Abstract-Aldosterone:renin ratio (ARR) is used to screen for hyperaldosteronism. Data regarding correlates of ambulatory ARR in the community and its relation to hypertension incidence are limited. We defined clinical correlates of ARR, determined its heritability, tested for association and linkage, and related ARR to blood pressure (BP) progression in nonhypertensive individuals among 3326 individuals from the Framingham Heart Study (53% women; mean age: 59 years Key Words: aldosterone Ⅲ renin Ⅲ hypertension, essential Ⅲ blood pressure Ⅲ genetics Ⅲ population Ⅲ risk factors A n elevated ratio of serum aldosterone to plasma renin level can point toward the diagnosis of primary hyperaldosteronism (PH), described first by Conn in 1955. 1 Recent studies using the aldosterone:renin ratio (ARR) as a screening measure have estimated the frequency of PH to be as much as 5% to 15%. [2] [3] [4] [5] [6] [7] Data regarding the clinical and genetic correlates of ARR in the general population are limited, particularly so in nonhypertensive individuals. In referral samples of hypertensive individuals, ARR (or its components aldosterone and renin) has been found to vary with age, 4,8 -11 sex, 9 body mass index and obesity, 12-14 blood pressure (BP) and hypertension, 15 diuretic 16 -18 and other antihypertensive use, 19 menopausal status, hormone replacement therapy, 20 -23 total/high-density lipoprotein cholesterol, 24,25 urinary sodium excretion, 8 posture, 18,26 time of day, 26 and race. 9, [27] [28] [29] 
Furthermore, the prognostic significance of ARR in community-based nonhypertensive individuals is unknown. We demonstrated recently that increasing serum aldosterone predicts a future increase in BP and incident hypertension in nonhypertensive participants in the Framingham Heart Study. 30 Subsequent to that investigation, we measured plasma renin concentrations in our cohort to evaluate the independent and conjoint contributions of both hormones to longitudinal BP outcomes using the ARR. Given the interest in ARR as a screening test and the emergence of novel antihypertensive agents targeting both renin and aldosterone, 31, 32 a study of the clinical and genetic correlates of ARR in the community and the influence of ARR on BP progression and hypertension incidence among nonhypertensive subjects could have diagnostic, therapeutic, and prognostic importance. Accordingly, we evaluated the clinical and genetic correlates of ARR and examined the relationship of ARR in nonhypertensive individuals to BP progression and incident hypertension in a large, community-based sample.
Methods

Study Participants
The design and selection criteria of the Framingham Offspring Study have been reported previously. 33 Approximately every 4 years, offspring study participants undergo detailed medical history, assessment of medication use, physical examination, and assessment of vascular risk factors. The present investigation included 3532 participants who attended the sixth examination cycle (1995) (1996) (1997) (1998) . The institutional review board at Boston Medical Center approved the study, and all of the participants gave written informed consent.
Participants were excluded if they were missing values for plasma renin (nϭ74), serum aldosterone (nϭ97), or any of the covariates (nϭ35). After exclusions, 3326 attendees were eligible for the study of clinical correlates. Heritability analyses were conducted in 2271 participants in 998 families. The genetic linkage analysis included 1225 genotyped participants in 328 families (1597 sibling pairs and 4 parent-offspring pairs). The association analysis included 1729 unrelated cohort participants with covariate and genotype data. Analyses of the relations of baseline ARR to BP progression and incident hypertension were restricted to the 1773 nonhypertensive participants at the sixth examination who attended the seventh examination.
Measurements of Plasma Renin, Serum Aldosterone, and BP
Fasting whole blood samples were drawn by venipuncture after Ϸ10 minutes of rest in a supine position in the morning, typically between 7:30 and 9:00 AM. Participants were instructed to take all routine medications. Blood samples were centrifuged and the serum/plasma fraction stored at Ϫ70 to Ϫ80°C until it was thawed for analysis. Plasma renin concentration (milliunits per liter) was measured using an immunochemiluminometric assay (Nichols Advantage Direct Renin assay). The assay was sensitive with intraassay coefficients of variation ranging from 2% for high concentrations to 10% for low concentrations. Serum aldosterone (nanograms per liter) was measured using a radioimmunoassay (Quest Diagnostics), as described previously. 34 Spot urinary sodium concentration was measured using an automated ion-electrode method and indexed to urinary creatinine (expressed as millimoles of sodium per gram of urinary creatinine), as described previously. 34 Participants rested in a chair for Ն5 minutes before BP measurement in the Framingham clinic. A physician measured systolic and diastolic BP twice in the left arm of seated participants with a mercury column sphygmomanometer, a cuff of appropriate size, and a standardized written quality control protocol. 35 The average of 2 readings constituted the examination BP.
Clinical Covariates
We considered the following potential covariates of ARR for analyses: age, sex, total:high-density lipoprotein cholesterol ratio, diabetes, menopausal status (premenopausal, postmenopausal with hormone replacement therapy, or postmenopausal without hormone replacement therapy), hypertension (systolic BP Ն140 mm Hg or diastolic BP Ն90 mm Hg at the sixth examination), and use of the following classes of antihypertensive agents: diuretics, angiotensinconverting enzyme (ACE) inhibitors, ␤-blockers, calcium channel blockers, ␣-1 adrenergic receptor antagonists, and other antihypertensive agents. Methods of risk factor ascertainment in the Framingham Heart Study have been reported elsewhere. 36 Because the urinary sodium:creatinine ratio was only available in a subset of 2850 participants, we performed secondary analyses adjusting for the urinary sodium:creatinine ratio.
Selection and Genotyping of Tag Single Nucleotide Polymorphisms and Microsatellites
We genotyped 32 polymorphic single nucleotide polymorphisms (SNPs) in a reference sample of 93 individuals of European ancestry, 37 spanning a genomic distance of 30 kb surrounding the REN locus. These data revealed 2 blocks of strong linkage disequilibrium (LD) defined using the "spine of LD" method implemented in Haploview 2.03 ( Figure S1 , available online at http://hyper. ahajournals.org). 38 We selected 14 tag SNPs for genotyping in the Framingham Heart Study samples that captured haplotypes within blocks at frequency Ն0.05 at an r 2 Ն0.8, 39 as well as an additional 3 SNPs to better define the region between the 2 blocks of strong LD. Genotyping of microsatellite markers at an average 10 cM spacing (Weber set 8A) for the linkage analyses in the related sample was conducted through the Mammalian Genotyping Center at Marshfield Clinic as described previously. 40 
Statistical Analysis
Renin and aldosterone levels were natural-log transformed because of their positively skewed distributions. We evaluated the sexspecific distributions of logARR in several participant subgroups: nonhypertensive; untreated hypertensive; and hypertensive on diuretics, ACE inhibitors, or ␤-blockers, separately. We used stepwise multivariable linear regression to evaluate the clinical correlates of logARR in the entire sample of 3326 participants. 41 We then used generalized estimating equations to account for correlations among related individuals 42 ; a PϽ0.05 was used for retention in the final multivariable model. We examined the correlates of log-aldosterone and log-renin separately to clarify whether any observed relation of logARR was driven by the relations of covariates to the numerator (aldosterone), the denominator (renin), or both. All of the analyses were carried out in SAS. 43 
Heritability and Genetic Analyses
For genetic analyses, we normalized the residuals from regression models (age-, sex-, and multivariable-adjusted) in the entire sample. Using variance components methods implemented in sequential oligogenic linkage analysis routines (SOLAR), 44 we determined the heritability of logARR residuals from age-, sex-, and multivariableadjusted models. We carried out multipoint linkage analysis using Genehunter 2.0 for the logARR residuals from both models. 45 Linkage results are reported in logarithm of the odds (LOD) scores. The LOD score is the log base 10 of the likelihood ratio under the hypotheses of linkage and nonlinkage. We tested the association of logARR residuals with each SNP (nϭ1729 unrelated subjects) individually using a 2-degree of freedom general test. Within the 2 blocks of strong LD, we tested haplotypes with frequency Ն0.05 for association with logARR residuals from age-, sex-, and multivariable-adjusted models using the score-based haplo.stat program (available at http://mayoresearch. mayo.edu/mayo/research/biostat/schaid.cfm). 46 We considered global haplotype tests as the primary statistical test of significance.
ARR Relation to BP Progression and Incident Hypertension
We used multivariable logistic regression to relate ARR (modeled as a continuous, log-transformed variable and as sex-specific quartiles) in nonhypertensive participants at examination 6 to the risk of progression of Ն1 BP category (optimal: Ͻ120/80 mm Hg, normal: 120 to 129/80 to 84 mm Hg, high normal: 130 to 139/85 to 89 mm Hg, hypertension: Ն140/90 mm Hg) 35 and incident hypertension (systolic BP: Ն140 mm Hg, diastolic BP: Ն90 mm Hg, or use of antihypertensive treatment) at examination 7 after a mean follow-up of 3 years. 47 We examined a model adjusting for age and sex and a multivariable model adjusting for age, sex, baseline BP stage, systolic BP, diastolic BP, smoking status, diabetes, serum creatinine, body mass index, and weight change percentage on follow-up, as described previously. 48 We performed secondary analyses incorporating urine sodium:creatinine ratio as a covariate. We tested for effect modification by age, sex, body mass index, and urine sodium:creatinine ratio by incorporating appropriate interaction terms in multivariable models with logARR. To understand the relative contributions of aldosterone versus renin to any potential association of ARR with BP progression and incident hypertension, we assessed rates of BP progression and incident hypertension by tertiles of aldosterone cross-classified by tertiles of renin; tertiles were used instead of quartiles to avoid small numbers in individual cells. Furthermore, we examined models that included continuous hormone levels of aldosterone and renin each alone and together as separate linear predictors and compared the results with models containing aldosterone and renin together as a fixed ratio (ARR).
Results
Characteristics of the study Cohort
The characteristics of the entire study sample and of the nonhypertensive individuals are shown in Table 1 . The cohort is middle-aged to elderly and of European descent. (17) 127 (20) 121 (10) 117 (12) Diastolic BP, mm Hg 77 (9) 74 (9) 75 (7) 71 (8) Hypertension at exam 6, % † 45 39
On any treatment 32 26 On diuretics 7 10 On ACE inhibitors 14 9
On ␤-blockers 12 9
On calcium channel blockers 12 8
On ␣-1 AR blockers 3 1 Values are reported as mean (SD) for continuous traits and % for dichotomous traits. Because serum aldosterone, plasma renin and ARR are skewed, median values ͓25th percentile to 75th percentile͔ are shown. CVD indicates cardiovascular disease; Na, sodium; Cr, creatinine; AR, adrenergic receptor; HDL, high-density lipoprotein.
*Nonhypertensive participants at baseline exam 6 were defined by systolic BP Ͻ140 mm Hg, diastolic BP Ͻ90mm Hg, and absence of antihypertensive treatment.
†Shown are the percentages of participants with treated or untreated hypertension. ‡Diabetes determined by use of hypoglycemic agents or fasting glucose Ն126 mg/dL. §Note that urine Na/Cr ratio was available for the subset of 1337 men and 1513 women. Shown is the percentage exceeding one among many thresholds proposed in screening hypertensive subjects for primary hyperaldosteronism. 49 Figure 1 displays the sex-specific distributions of ARR for the following subgroups: nonhypertensive, untreated hypertensive, hypertensive on a diuretic, hypertensive on ACE inhibitors, and hypertensive subjects on ␤-blockers. The ARR was higher in women than in men and in untreated hypertensive subjects compared with nonhypertensive subjects. The ARR was lower in men and women on ACE inhibitors and higher in men and women on ␤-blockers compared with untreated hypertensive subjects. Overall, ARR values exceeded 26 ng/L per mU/L (only 1 screening threshold among many proposed in the literature 49 ) in 7.9% and 23.1% of untreated hypertensive men and women and in 24.6% and 31.1% of men and women on ␤-blockers. This threshold was exceeded by 3.1% of nonhypertensive men and 8.8% of nonhypertensive women (Figure 1 ).
Distribution of ARR
Clinical Correlates of LogARR
Log-renin was positively associated with the use of diuretics and ACE inhibitors and inversely related to age, female sex, hypertensive status, and ␤-blocker and hormone replacement therapy use (Table 2) . We confirmed our previously reported 34 finding that serum aldosterone was positively associated with female sex and diuretic use and demonstrated an additional positive association with calcium channel blocker use and a negative association with ACE inhibitor use ( Table 2 ). In stepwise regression modeling, logARR was positively related to age, female sex, hypertensive status, total cholesterol:highdensity lipoprotein cholesterol ratio, and ␤-blocker and hormone replacement therapy use (Table 2) . We observed that logARR was inversely related to diuretic and ACE inhibitor use. Several covariates were not significantly related to log-renin or log-aldosterone individually but were significant correlates of logARR ( Table 2 ). The multivariable-adjusted logARR model explained 28% of the interindividual variation in ARR. The inclusion of urinary sodium:creatinine ratio as a covariate minimally altered the regression coefficients for other covariates (data not shown).
Heritability and Linkage
The heritability for age and sex-adjusted logARR was 0.36 (SE: 0.06; PϽ10
Ϫ4
) and for multivariable-adjusted logARR was 0.40 (SE: 0.06; PϽ10
). The heritability of multivariable-adjusted log-renin was 0.22 (SE: 0.06; PϽ10
). The heritability of multivariable-adjusted log-aldosterone as modeled here was 0.11 (SE: 0.05; Pϭ0.01), quite consistent with our previous report on aldosterone that used slightly different covariates in the model. 34 Exclusion of all of the individuals on antihypertensive therapy reduced the sample size substantially (740 sibpairs), so models including antihypertensive users with adjustment for treatment were considered the primary analysis.
The results of genome-wide linkage analysis of multivariableadjusted logARR are shown in Figure 2 . We observed modest evidence of linkage to chromosome 11p with a maximum multipoint LOD score of 1.89 at 2 cM and to chromosome 5p with a maximum multipoint LOD score of 1.60 at 30.8 cM for residuals from multivariable-adjusted models. In an initial analysis, we did not adjust for ACE inhibitor and ␤-blocker use when generating logARR residuals. In linkage analyses of those residuals, we observed suggestive evidence of linkage to a locus on chromosome 7p21-22 (24.6 cM) with a maximum multipoint LOD score of 2.94 and 2.78 for age-, sex-, and multivariableadjusted ARR, respectively. However, adjusting for ACE inhibitor and ␤-blocker use in the multivariable-adjusted models (our principal analytical strategy) resulted in a LOD score at this locus of 1.14. To explore the attenuation of the linkage signal with more complete drug class modeling, we conducted linkage analysis on chromosome 7p in participants without ACE inhibitor use (LOD: 0.43), without ␤-blocker use (LOD: 2.02), and in individuals using neither (LOD: 0.53). These results raise the possibility of confounding of linkage results in the larger sample by ACE inhibitor use when not adjusted for.
Single SNP and Haplotype Association Results
We genotyped 32 SNPs falling in 2 blocks of strong LD in the Centre d'Etude du Polymorphisme Humain (CEPH) reference samples to construct a high-resolution LD map of the REN locus with an average inter-SNP distance of 880 bp ( Figure S1 ). In the 1729 unrelated participants, we genotyped 17 SNPs that capture the majority of common variation across the REN locus.
We tested 17 SNPs across the REN locus and observed no single SNP to have a nominal PϽ0.01 for association with logARR (Table S1 ). We tested all of the haplotypes with frequency Ն5% in the 2 blocks of strong LD across the REN locus and found no global PϽ0.01.
Relations of ARR to BP Progression and Incident Hypertension
On follow-up (mean: 3.0 years), 607 nonhypertensive individuals (34.2%) experienced BP progression, and 283 (16.0%) developed hypertension. The rates of BP progression and hypertension incidence rose across ARR quartiles in graded fashion (Table 3) . In multivariable analyses, an SD increment in logARR was associated with a 23% increased risk of BP progression (PϽ0.0001) and a 16% increased risk of hypertension (Pϭ0.05). The top ARR quartile was associated with an 89% increased risk of BP progression (PϽ0.0001) and a 53% increased risk of hypertension (Pϭ0.045) compared with the lowest ARR quartile. Models incorporating urine sodium:creatinine ratio yielded essentially similar results (data not shown). We did not observe any effect modification by age, sex, body mass index, or urine sodium:creatinine ratio on risk of BP progression or incident hypertension.
Rates of BP progression and incident hypertension rose across increasing tertiles of aldosterone (for any tertile of renin) and decreased across increasing tertiles of renin (for any tertile of aldosterone; Figure 3 ). To better understand the contributions of aldosterone and renin to the prognostic ability of ARR, we compared age-, sex-, and multivariableadjusted models predicting BP progression and incident hypertension that incorporated aldosterone and renin, separately and together as linear predictors, as well as in a fixed ratio (ARR; Table 4 ). ␤-Coefficients for log-aldosterone and log-renin incorporated in separate multivariable models were opposite in direction (positive for log-aldosterone and negative for log-renin) and statistically significant with the exception of log-renin for the outcome of incident hypertension (Pϭ0.004 and 0.02 for log-aldosterone for BP progression and incident hypertension; correspondingly, Pϭ0.04 and 0.77 for log-renin; Table 4 ). Models incorporating both log-aldosterone and log-renin together as linear predictors had gen- ␤ indicates linear regression coefficient; AR, adrenergic receptor; HRT, hormone replacement therapy; HDL, high-density lipoprotein. Covariates tested in stepwise multivariable regression included (data not shown): age, sex, diastolic BP, systolic BP, hypertension, ACE inhibitor use, ␤-blocker use, calcium channel blocker use, and ␣-1 adrenergic receptor antagonist use, total:high-density lipoprotein cholesterol, postmenopausal on hormone replacement therapy, and postmenopausal not on hormone replacement therapy. Shown are the ␤-coefficients, fold change in ARR, 95% CI, and P for all covariates significant at PϽ0.05 in GenMod linear regression modeling, accounting for sibling correlations. For comparison, the ␤-coefficients (SE) for the covariates in models predicting log-aldosterone and log-renin are shown. Note that coefficients for covariates predicting log-aldosterone differ from those previously published 30 because of differences in regression modeling and samples. A ␤-coefficient for age of 0.11 indicates that for a 10-year increase in age, the ARR increases 1.11-fold (e ␤ ) or by 11%. *PϽ0.0001.
†PϽ0.01. ‡The hypertensive group is compared with the nonhypertensive group. §The postmenopausal state, on or not on hormone replacement therapy, is compared with the premenopausal state.
erally higher c-statistics compared with models incorporating either hormone alone. In these models, log-aldosterone and log-renin had ␤-coefficients more extreme in magnitude and, again, opposite in direction (for BP progression, Pϭ0.0002 and 0.002 for log-aldosterone and log-renin, respectively; for hypertension incidence, Pϭ0.01 and 0.19 for log-aldosterone and log-renin, respectively; Table 4 ). Models with ARR did not differ substantially from models containing both log-aldosterone and log-renin as separate linear predictors (cstatistics of 0.68 to 0.69 and 0.82 for BP progression and hypertension incidence, respectively, for both sets of models).
Discussion
We observed significant association of ARR with several clinical factors in our ambulatory community-based sample. ARR demonstrated significant heritability, and we identified 2 chromosomal regions with modest evidence of linkage to ARR. We did not find significant association of ARR with 17 common variants across the renin gene (REN) locus. In nonhypertensive participants, we observed that a graded increase in baseline ARR was associated with significantly increased risk of BP progression and incident hypertension in a continuous fashion and that renin and aldosterone are jointly more predictive of BP outcomes than either hormone alone. To our knowledge, the current report is the largest study of the correlates of ARR in a community-based setting. Olivieri et al 4 have reported the distribution of ARR values in a community-based sample of hypertensive subjects withdrawn from antihypertensive agents, but that study did not examine the entire BP distribution in the community or explore several potential covariate relations to ARR. The significant associations of ARR with age, sex, use of ACE inhibitors, ␤-adrenergic receptor blockers, diuretics, and hormone replacement therapy observed in our sample are consistent with previous reports. 9,16 -22,50 -52 Our finding of the association of higher total:high-density lipoprotein cholesterol ratio with increased ARR differs from the results of a previous report that investigated people on a high-salt diet. 25 We examined the distribution of ARR in nonhypertensive participants and in untreated and treated hypertensive participants. We observed that ARR level in individuals on ACE inhibitors was significantly lower and on ␤-blockers was significantly higher compared with untreated hypertensive individuals. This is in agreement with previous findings in 
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which hypertensive subjects were randomly assigned to ACE inhibitor and ␤-blocker therapy. 19 We noted significant heterogeneity in the proportion of hypertensive participants exceeding 1 among many thresholds proposed for PH screening (ARR Ͼ26 ng/L per mU/L), according to their sex and treatment status. 49 Given the differences in ARR by hypertension and treatment status, as well as by multiple covariates, the use of a single threshold in diagnostic testing of population-based samples may not be appropriate. We demonstrated the heritability of multivariable-adjusted ARR to be 0.40, higher than for aldosterone 34 or renin alone. We are unaware of other studies that have sought to quantify the heritability of ARR in unselected individuals in the community, although familial aggregation of hyperaldosteronism has been demonstrated (eg, familial hyperaldosteronism type II). 53 Evidence of substantial heritability of plasma renin activity has been reported in some studies, 54, 55 but other investigators have reported more modest evidence that heritable factors influence renin. 56, 57 We observed modest evidence that a locus on chromosome 11p is linked to ARR (multivariable-adjusted ARR LOD score 1.89) and 5p (LOD 1.60). The REN and CYP11B2 (aldosterone synthase gene) loci, residing on different chromosomes, had no significant linkage signals. A review of known genes under the 2 linkage peaks with LODϾ1.5 revealed few obvious candidate genes on the basis of involvement in steroid metabolism or renal physiology: natriuretic peptide receptor C/guanylate cyclase (NPR3, chromosome 5) and 3-hydroxy-3-methylglutaryl-coenzyme A synthase 1 (HMGCS1, chromosome 5). 58 However, the possibility of a false-positive result cannot be excluded. Replication in other samples would be essential before further examination of candidate genes under any linkage peak would be warranted. We note that, in linkage analysis without adjustment for ACE inhibitor or ␤-blocker use, we observed suggestive evidence of linkage to a region on chromosome 7p that has been linked previously to ARR in families with familial hyperaldosteronism II or nonglucocorticoid remediable hyperaldosteronism. 59, 60 However, the statistical support for linkage to this locus was markedly attenuated when we adjusted for use of specific antihypertensive therapy. The marked attenuation in the linkage signal observed with exclusion of ACE inhibitor users supports familial aggregation of medication use as a potential cause of the linkage signal that we observed in analyses that did not account for medication use in the regression models. We are unaware of any previous linkage study of ARR in an unselected community-based sample that included a wide spectrum of hypertensive and nonhypertensive subjects.
We observed no clear association of 17 common genetic variants across the REN locus with ARR, although small effects could have been missed. Our study of common variants cannot assess the possibility that rare variants at this locus contribute to ARR. Moreover, the lack of linkage to the REN locus does not exclude a possible influence of rare or common variants on ARR given the limited statistical power of linkage for complex traits. 61 Among nonhypertensive participants, we observed a strong and graded influence of baseline ARR on the risk of BP progression and incident hypertension on 3-year follow-up. .0, and Q4 Ͼ10.0; women Q1 Ͻ5.6, Q2 5.6 to 9.6, Q3 9.6 to 15.0, and Q4 Ͼ15.0. The multivariable model was adjusted for age, baseline BP stage, systolic BP, diastolic BP, smoking status, diabetes, creatinine, body mass index, and percentage of weight change on follow-up. The first ARR quartile, Q1, was used as the referent category. Three dummy variables of ARR corresponding to Q2, Q3, and Q4 were included in the multivariable models of quartiles, and in the trend analysis across quartiles, the ARR quartile variable (coded 0, 1, 2, and 3) was included. 1 SD of logARR ϭ 0.7.
*Age-and sex-adjusted.
These findings extend our earlier report linking serum aldosterone assessed alone to the risk of BP progression and hypertension. 30 We observed that aldosterone and renin independently and jointly predict future BP progression and hypertension and that this effect is not driven by 1 hormone alone. The temporal relationship suggests that the renin-angiotensin system contributes to the development of hypertension in nonhypertensive individuals, but our study cannot exclude the possibility that ARR is simply a marker (as opposed to a risk factor) of incipient hypertension. Examination of the role of the renin-angiotensin system in BP change over time could yield insights into BP physiology and suggest novel targets for preventive strategies. We are not aware of any published reports linking ARR to hypertension incidence in the community. The large, community-based sample, the adjustment for multiple clinical covariates, the comprehensive evaluation of heritability, linkage and association with variation at the REN locus, and the longitudinal follow-up to assess prognostic significance of ARR strengthen our investigation. Nonetheless, several limitations must be acknowledged. We examined ambulatory ARR measurements in people on a random sodium diet who were not withdrawn from antihypertensive medications. The constraints of a large, longitudinal observational cohort precluded a longer duration in the supine position, standardization of sodium intake, or medication withdrawal. However, not controlling these factors would be expected to bias our findings toward the null rather than toward the false inference of association. Our study reflects a community-based sample and is not directly comparable to the examination of hypertensive subjects in a research setting to diagnose hyperaldosteronism. The middle-age-to-elderly composition and predominant European ancestry of our cohort may limit the generalizability of our results to younger individuals or those of different ancestry; racial differences in serum aldosterone and renin values have been reported. 9 We tested for association with SNPs at the REN locus but not at the CYP11B2 (aldosterone synthase) locus; a comprehensive set of SNP genotypes at CYP11B2 was not available. The finding that ARR predicts BP progression and incident hypertension does not address the use of population-based screening of nonhypertensive subjects, which would require studies designed to address this specific question. Lastly, our community-based study cannot address the role of ARR for identifying individuals with PH, because we did not carry out further diagnostic testing beyond the assessment of ARR. Rates of BP progression and incident hypertension among nonhypertensive participants. Age-and sex-adjusted incidence rates of BP progression (A) and incident hypertension (B) at a mean of 3 years are shown across tertiles of aldosterone (A1 to 3ϭfirst to third tertiles) and renin (R1 to 3ϭfirst to third tertiles). Graded, continuous increases in the risk of BP progression and incident hypertension are found across increasing aldosterone and decreasing renin tertiles. Olive and black error bars represent lower and upper 95% confidence bounds.
Perspectives
In our large, community-based sample, ARR varied with some clinical characteristics, suggesting that these features be taken into consideration when interpreting ARR values in ambulatory settings. Genetic factors influence ARR as evidenced by significant heritability; ongoing and planned genome-wide genotyping in the Framingham Heart Study may identify variants that influence ARR. We found that ARR has a higher heritability than either aldosterone or renin alone and that aldosterone and renin are independent predictors of BP progression and incident hypertension. The accruing evidence that interindividual variation in ARR predicts BP progression, hypertension, and myocardial infarction 62, 63 raises the possibility that identifying genetic and nongenetic contributors to ARR could refine our understanding of the biology of the renin-angiotensin system, identify novel therapeutic targets, and improve risk prediction.
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